Introduction
============

Gastric cancer is one of the most common cancers worldwide. Despite the incidence of gastric cancer has declined in the past few decades, there is still a high prevalence of gastric cancer in the Eastern Asia including China [@B1]. Moreover, although the mortality of gastric cancer has a conspicuous decline with the improvement of clinical treatment in the last decade, the prognosis of gastric cancer is still poor with about 20% five-year survival rates [@B2]. Gastric cancer is a heterogeneous and complex disease resulting from the interaction of genetic and environmental factors, including*helicobacter pylori* infection [@B3], dietary habit [@B4], smoking and drinking [@B5].

Long non-coding RNAs (lncRNAs) are non-coding transcripts longer than 200 nucleotides. Recent studies have revealed that the lncRNAs involved in the tumorigenesis for their function as proto-oncogene [@B6] or anti-oncogene [@B7]. Moreover, the differential expression of lncRNAs was observed in different cancers, including prostate cancer [@B8], hepatocellular carcinoma [@B9], colon cancer [@B10], and gastric cancer [@B11]. Studies have also suggested that polymorphism in lncRNAs may influence the process of splicing and stability of messenger RNA (mRNA) conformation, leading to the modification of their interacting partners [@B12], [@B13]. Thus, the susceptibility of polymorphisms in lncRNAs to risk of cancers has been investigated among several ethnicities [@B14], [@B15]. Moreover, the polymorphisms in the region of 8q24 chromosomal gene-poor region, known as \'gene desert\', have been consistently implicated in genome-wide association studies as susceptibility loci for cancers, including prostate cancer, colorectal cancer, and breast cancer [@B16], [@B17], [@B18].

Prostate cancer non-coding RNA 1(*PRNCR1*), a lncRNA transcribed from 8q24, involved in the carcinogenesis of prostate cancer through activating androgen receptor (AR) [@B13], and polymorphisms in the lncRNA *PRNCR1*were observed as risk of various cancers, including prostate cancer [@B13], colorectal cancer[@B19] , and gastric cancer[@B20]. Moreover, in the 8q24 region, lncRNAs*PCAT1* and *CCAT2*have potential roles in promoting cancer pathogenesis through affecting double-stranded DNA break repair [@B21] and chromosome instability [@B22], and polymorphisms in these lncRNAs were potential risks of cancers [@B23]. Based on this background, we performed this study to assess the susceptibility of polymorphisms (*PRNCR1*: rs7463708, rs7007694, rs16901946, rs13252298; *PCAT1*: rs1026411, rs12543663; CCAT2: rs6983267) in the lncRNAs in the region of 8q24 to risk of gastric cancer, and the prognostic value of these polymorphisms for gastric cancer patients was also evaluated by the overall survival (OS) days.

Materials and Methods
=====================

Study subjects
--------------

A total of 494 gastric cancer patients and same number age- and sex-matched healthy controls were enrolled for this case-control study. All the patients were histologically diagnosed as gastric cancer from January 2009 to January 2014 in Nanjing First Hospital, Nanjing Medical University. Individuals who came to the hospital for routine physical examination were recruited as health controls. All the participants were heritably unrelated ethnic Han Chinese from the same geographic region of Nanjing City, the capital of Jiangsu province, which lies in the middle of the east of China. The characteristics of each subject, including age, gender, smoking, drinking, were collected via a questionnaire. Individuals who had smoked daily for more than one year were considered smokers, and those who consumed one or more alcoholic drinks per week for at least one year were considered drinkers.

For patients, the clinical features, such as tumor size, distant metastasis, depth of invasion, etc., were collected from the patients\' medical records. Moreover, the TNM stages were examined and evaluated by the TNM classification according to American Joint Commission for Cancer Staging in 2002, the sixth edition. The patients were followed up at 3-month intervals, and the follow-up information on survival period of patients was updated by a trained clinical specialist through on-site interview, direct calling or medical chart review. The latest follow-up data in this analysis were obtained in June 2016, and finally, a total of 488 patients were traced with periods up to four years,

The protocol of this study was approved by the Institutional Review Board of the Nanjing First Hospital, and written informed consents were obtained from all participants.

DNA extraction and genotyping
-----------------------------

The genotypes were detected as we previously described [@B24], [@B25]. In brief, DNA was extracted from whole-blood samples and concentrated by using GoldMag-Mini Whole Blood Genomic DNA Purification Kit according to the manufacture\'s protocol (GoldMag Co. Ltd. Xi\'an, China), and then DNA purity was measured by spectrometry (DU530 UV/VIS spectrophotometer, Beckman Instruments, Fullerton, CA, USA). All samples were genotyped for the seven polymorphisms by the Sequenom MassARRAY platform, according to the standard protocol recommended by the manufacturer with a Sequenom Mass-ARRAY ® RS1000 (Sequenom, Inc.). Multiplexed SNP MassEXTENDED assay was designed by Sequenom MassARRAY Assay Design 3.0 Software [@B26]. Finally, data management and analysis were performed by Sequenom Typer 4.0 Software [@B26], [@B27].

H. pylori serum assays
----------------------

The *H. pylori* infection of all participants were determined by using a commercial *H. pylori* immunogold testing kit (Kangmei Tianhong Biotech (Beijing) Co., Ltd, Beijing, China) according to the suggested procedures. The test has been validated with sensitivity of 98.29% and specificity of 98.51% for the detection of *H. pylori*infection in the Chinese populations.

Statistical analysis
--------------------

The statistical analysis for genotype distribution was performed by the χ2 test with SPSS 11.0 for Windows (SPSS, Chicago, IL, USA). Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using a logistic regression model. Hardy-Weinberg equilibrium in the control group was tested using a goodness of fit chi-square test. Hazard ratios (HRs) were calculated by multivariate Cox regression analysis. The P value \< 0.05 was considered statistically significant difference.

Results
=======

Characteristics of the study population
---------------------------------------

The demographic and exposure data of all participants are summarized in Table [1](#T1){ref-type="table"}. There was no significant difference in *helicobacter pylori* infection rate (cases:56.28%, controls:51.62%, p=0.110), age (p=0.718), sex (p=0.943), smoking (p=0.765) and drinking status (p=0.530) between cases and controls. For the tumor stage, a total of 130 (26.32%) and 364 (73.68%) patients were classified to TNM stage T1-T2 and T3-T4, respectively. For the tumor site, a total of 142 (28.74%) and 352(71.26%) patients were diagnosed as gastric cardia adenocarcinoma (GCA) and non-gastric cardia adenocarcinoma (NGCA), respectively.

Association between polymorphisms and risk of gastric cancer
------------------------------------------------------------

The genotype distributions of the polymorphisms in cases and controls are presented in Table [2](#T2){ref-type="table"}. The observed frequencies of all tested genotypes in controls did not deviate from Hardy-Weinberg equilibrium (HWE) (rs16901946: p=0.150; rs13252298: p=0.145; rs7463708: p=0.390; rs7007694: p= 0.111; rs12543663: p=0.802; rs1026411: p=0.077; rs6983267: p=0.587).

The genotype distributions between the cases and controls were significantly different for rs16901946 (p=0.015), but not for rs13252298 (p=0.217), rs7463708 (p=0.362), rs7007694 (p=0.603), rs12543663 (p=0.904), rs1026411 (p=0.627) and rs6983267 (p=0.870). When the rs16901946 AA genotype was used as the reference, the G allele carriers have a higher risk of gastric cancer (AG: adjusted OR = 1.33, 95% CI =1.02-1.73, p=0.033; GG: adjusted OR = 2.07, 95% CI = 1.11-3.86, p=0.023; AG/GG: adjusted OR = 1.39, 95% CI = 1.08-1.79, p=0.011) after adjustment for age, gender, smoking, drinking, and *Helicobacter pylori* infection status. In the additive model, rs16901946 was also observed for the increased risk of gastric cancer (adjusted OR = 1.37; 95% CI = 1.10-1.70, p=0.004). However, there was no significant association between with the other six polymorphisms and gastric cancer risk.

Stratification analysis
-----------------------

To further assess the risk of rs16901946 to gastric cancer, a stratified analysis was performed by subgroups of age, sex, *Helicobacter pylori* infection status, tumor stage and tumor site using co-dominant model (AG/GG *vs.* AA) (Table [3](#T3){ref-type="table"}). The increased risk for rs16901946 G allele carriers (AG/GG) was more evident in sub-group of younger subjects (adjusted OR = 1.84, 95% CI = 1.18-2.87, p=0.007), males (adjusted OR = 1.55, 95% CI = 1.15-2.08, p=0.004), positive *Helicobacter pylori* infection (adjusted OR = 1.44, 95% CI = 1.02-2.03, p=0.041), GCA (adjusted OR = 1.61, 95% CI = 1.10-2.35, p=0.014), and tumor stage T1-T2 (adjusted OR = 1.58, 95% CI = 1.10-2.28, p=0.013), suggesting the risk was enhanced by the potential interactions between rs16901946 and age, sex, *Helicobacter pylori* infection.

Association between polymorphisms and clinical outcome
------------------------------------------------------

A total of 488 patients were traced for follow-up information on survival period. The association of the polymorphisms with OS of patients was assessed for the predictive value by patients with heterozygous or homozygous genotype compared with those with wild genotype. The result revealed that no polymorphism was associated with OS of patients (Table [4](#T4){ref-type="table"}), indicating these polymorphisms have no significantly predicted value for gastric cancer.

Discussion
==========

This population-based case-control study recruited 494 gastric cancer patients and 494 age- and sex- matched healthy controls in a Chinese population, and demonstrated that rs16901946 was associated with increased risk of gastric cancer, especially for individuals with younger age (≤60), male, positive *Helicobacter pylori* infection status, GCA, and gastric cancer in stage T1-T2.

The lncRNA *PRNCR1* was reported to promote the carcinogenesis of prostate through activating androgen receptor [@B13], which is a member of the nuclear receptor family acting as a transcription factor [@B28]. Rs16901946 in the lncRNA*PRNCR1* was reported to be associated with risk of cancers [@B23], and it might affect the predicted secondary structure of *PRNCR1* mRNA, and change the stability of lncRNA *PRNCR1* or the mRNA conformation leading to the modification of its interacting partners [@B13]. Previously, Li et al. reported that there was no association of rs16901946 to the risk of colorectal cancer [@B19] and gastric cancer [@B20], which was not consistent to the result of this study. The inconsistent conclusion may due to several factors; firstly, their studies were performed on the population from Sichuan province, west of China, but this study based on the population from Jiangsu province, east of China; secondly, this study observed the significant association of rs16901946 to gastric cancer risk was more obvious in the subgroup of GCA(adjusted OR=1.61, 95% CI=1.10-2.35, p= 0.014) and then in NGCA(adjusted OR=1.32, 95% CI=1.00-1.74, p=0.051); however, regrettably, the cases in their study were not classified; thirdly, this study suggested that the interaction between *Helicobacter pylori*infection and rs16901946 leads to higher risk of gastric cancer, and the ratio of *Helicobacter pylori*infection in this study was 56.28% and 51.62% in cases and controls, respectively, but this data was not included in their studies, and finally, the sample size of this study was larger than theirs, which may also cause the different conclusions.

Sub-group analysis revealed that rs16901946 G allele carriers and with younger age (≤60), male, and positive *Helicobacter pylori* infection status have higher gastric cancer risk, indicating the interaction of *Helicobacter pylori* infection and rs16901946 enhanced the risk of gastric cancer, which was consistent to the fact that *Helicobacter pylori* infection is a risk of gastric cancer. In China, actually, there is a fact that the ration of drinking and smoking is higher in male than in female; moreover, the prevalence of gastric cancer in male is higher than in female, which may contribute the different risk among the gender. Individuals with younger age have different life style compared with the older, such as work pressure, less time to relaxing, etc, which may enhance the risk of gastric cancer. The sub-group analysis revealed that rs16901946 was associated with the cancer type of GCA, and in stage T1-T2, indicating lncRNA *PRNCR1* contribution to the carcinogenesis of gastric cancer may modify by the cancer type. To our knowledge, there was no study reporting association between rs16901946 and gastric cancer risk. Thus, study with a large sample size and stratified analysis should be performed to confirm this result.

The value of all enrolled polymorphisms for predicting the survival of patients with gastric cancer was also analyzed, and no significant association was observed between these polymorphisms and OS, indicating these polymorphisms including rs16901946 could not be applied as a marker to predict the progress of gastric cancer. Similarly, in the prostate cancer, study concluded that lncRNA *PRNCR1* was not a prognostic marker [@B29], which was consistent to the result of this study.

Some limitations of this study should be noted. Firstly, the sample size of this study was relatively small, which may limit the statistical power, particularly in the multiple stratified analyses. Secondly, several potential environmental factors, such as diet, physical exercise, history of gastric diseases, were not included in this study, which may influence gastric cancer risk. Finally, the polymorphisms were included based on previous knowledge of their potential functional roles in the occurrence of cancers, but their functions were not clear.

In conclusion, this case-control study provided the evidence that rs16901946 in the lnc*PRNCR1*were associated with gastric cancer risk, and the risk could be enhanced by the interactions between the polymorphism and age, sex, *Helicobacter pylori* infection.
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lncRNA

:   long non-coding RNA

mRNA

:   messenger RNA

PRNCR1

:   prostate cancer non-coding RNA 1

AR

:   androgen receptor

OS

:   overall survival

HR

:   hazard ratio

CI

:   confidence interval

GCA

:   gastric cardia adenocarcinoma (GCA)

NGCA

:   non-gastric cardia adenocarcinoma.

###### 

Frequency distribution of demographic characteristics of gastric cancer cases and cancer-free controls.

  Variables                                   Cases, n (%)   Controls, n (%)   *P* value
  ------------------------------------------- -------------- ----------------- -----------
  **Age (mean ± SD)**                         64.61±11.82    64.88±11.80       0.718^a^
  \>60                                        324(65.59)     327(66.19)        0.840^b^
  ≤60                                         170(34.41)     167(33.81)        
  **Gender**                                                                   
  Male                                        362(73.28)     362(72.28)        1.000^b^
  Female                                      132(26.72)     132(26.72)        
  **Drinking**                                                                 
  Yes                                         54(10.93)      48(9.72)          0.530^b^
  No                                          440(89.07)     446(90.28)        
  **Smoking**                                                                  
  Yes                                         116(23.48)     120(24.29)        0.765^b^
  No                                          378(76.52)     374(75.71)        
  ***Helicobacter pylori*infection status**                                    
  Positive                                    280(56.28)     255(51.62)        0.110^b^
  Negative                                    214(43.72)     239(48.38)        
  **Clinical stages**                                                          
  T1-T2                                       130(26.32)                       
  T3-T4                                       364(73.68)                       
  **Tumor site (T1-T4)**                                                       
  GCA                                         142(28.74)                       
  NGCA                                        352(71.26)                       

GCA, gastric cardia adenocarcinoma; NGCA, non-gastric cardia adenocarcinoma.

^a^ Independent *t*-test.

^b^ Two-sided χ2 test for distributions between cases and controls. Table [2](#T2){ref-type="table"} Logistic regression analysis of association between the polymorphisms and gastric cancer risk.

###### 

Logistic regression analysis of association between the polymorphisms and gastric cancer risk.

  Genotypes        Cases, n(%)   Controls, n(%)   OR (95% CI)^a^    p-Value
  ---------------- ------------- ---------------- ----------------- ---------
  **rs16901946**                                                    
  AA               261(52.83)    301(60.93)       Reference         
  AG               203(41.09)    176(35.63)       1.33(1.02,1.73)   0.033
  GG               30(6.07)      17(3.44)         2.07(1.11,3.86)   0.023
  AG/GG            233(47.17)    193(39.07)       1.39(1.08,1.79)   0.011
  Additive model                                  1.37(1.10,1.70)   0.004
  **rs13252298**                                                    
  AA               236(47.77)    209(42.31)       Reference         
  AG               215(43.52)    235(47.57)       0.81(0.62,1.06)   0.120
  GG               43(8.70)      50(10.12)        0.79(0.50,1.24)   0.303
  AG/GG            258(52.23)    285(57.69)       0.82(0.64,1.05)   0.098
  Additive model                                  0.85(0.70,1.04)   0.113
  **rs7463708**                                                     
  TT               241(48.79)    228(46.15)       Reference         
  GT               209(42.31)    209(42.31)       0.95(0.73,1.24)   0.690
  GG               44(8.91)      57(11.54)        0.73(0.47,1.12)   0.151
  GT/GG            253(51.21)    266(53.85)       0.90(0.70,1.16)   0.428
  Additive model                                  0.89(0.74,1.08)   0.225
  **rs7007694**                                                     
  TT               264(53.44)    272(55.06)       Reference         
  CT               199(40.28)    198(40.08)       1.04(0.80,1.35)   0.760
  CC               31(6.28)      24(4.86)         1.32(0.75,2.34)   0.339
  CT/CC            230(46.56)    222(44.94)       1.07(0.83,1.38)   0.599
  Additive model                                  1.09(0.88,1.34)   0.441
  **rs12543663**                                                    
  AA               426(86.23)    425(86.03)       Reference         
  CA               66(13.36)     66(13.36)        1.00(0.69,1.44)   0.993
  CC               2(0.40)       3(0.61)          0.68(0.11,4.17)   0.680
  CA/CC            68(13.77)     69(13.97)        0.99(0.69,1.42)   0.945
  Additive model                                  0.98(0.69,1.38)   0.890
  **rs1026411**                                                     
  GG               186(37.65)    188(38.06)       Reference         
  GA               230(46.56)    218(44.13)       1.05(0.79,1.38)   0.753
  AA               78(15.79)     88(17.81)        0.91(0.63,1.32)   0.616
  GA/AA            308(62.35)    306(61.94)       1.01(0.78,1.31)   0.950
  Additive model                                  0.97(0.81,1.16)   0.725
  **rs6983267**                                                     
  TT               167(33.81)    172(34.82)       Reference         
  GT               233(47.17)    234(47.37)       1.03(0.77,1.36)   0.864
  GG               94(19.03)     88(17.81)        1.08(0.75,1.55)   0.677
  GT/GG            327(66.19)    322(65.18)       1.04(0.80,1.35)   0.776
  Additive model                                  1.04(0.87,1.24)   0.666

^a^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori*infection*.*

###### 

Stratification analysis for associations between rs16901946 and gastric cancer risk

  ------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                   Cases/Controls   AG/GG *vs.* AA\   p-Value                                             
                                                               OR (95% CI)^a^                                                        
  ------------------------------------------- ---------------- ----------------- --------- --------- ------------- ----------------- -------
  **Age, year**                                                                                                                      

  ≤60                                         86/109           50.59/65.27                 84/58     49.41/34.73   1.84(1.18,2.87)   0.007

  \>60                                        175/192          54.01/58.72                 149/135   45.99/41.28   1.22(0.89,1.67)   0.212

  **Gender**                                                                                                                         

  Male                                        189/228          52.21/62.18                 173/135   47.79/37.19   1.55(1.15,2.08)   0.004

  Female                                      72/73            54.55/55.73                 60/58     45.45/44.27   1.02(0.62,1.68)   0.943

  ***Helicobacter pylori*infection status**                                                                                          

  Positive                                    146/156          52.14/61.18                 134/99    47.86/38.82   1.44(1.02,2.03)   0.041

  Negative                                    115/145          53.74/60.67                 99/94     46.26/39.33   1.32(0.91,1.93)   0.140

  **Tumor site**                                                                                                                     

  GCA                                         70/301           49.30/60.93                 72/193    50.70/39.07   1.61(1.10,2.35)   0.014

  NGCA                                        191/301          54.26/60.93                 161/193   45.74/39.07   1.32(1.00,1.74)   0.051

  **Clinical stages**                                                                                                                

  T1-T2                                       78/301           49.37/60.93                 80/193    50.63/39.07   1.58(1.10,2.28)   0.013

  T3-T4                                       183/301          54.46/60.93                 153/193   45.54/39.07   1.31(0.99,1.74)   0.057
  ------------------------------------------------------------------------------------------------------------------------------------------

^a^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori*infection*.*

###### 

Analysis of associations between the polymorphisms and clinical outcome of gastric cancer

  Polymorphism   HR(95% CI)^a,b^    p-Value
  -------------- ------------------ ---------
  rs16901946     0.98 (0.78-1.23)   0.850
  rs7463708      0.90 (0.71-1.13)   0.347
  rs12543663     1.12 (0.81-1.55)   0.477
  rs13252298     1.13 (0.90-1.43)   0.293
  rs7007694      0.97 (0.77-1.22)   0.778
  rs6983267      0.97 (0.76-1.23)   0.790
  rs1026411      0.82 (0.65-1.04)   0.108

HR, hazard ratio.

^a^ Cox regression based on heterozygous or homozygous genotype compared with wild genotype.

^b^Adjusted for age, gender, smoking, drinking, and *Helicobacter pylori*infection.
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